Ethical interactions help ensure that medical decisions are made in the best interests of patients. To achieve this, the Mexico City Declaration for Voluntary Codes of Business Ethics in the Biopharmaceutical Sector enumerated principles that should guide relationships between the pharmaceutical sector and the health care community.
The Mexico City Declaration, endorsed by Asia Pacific Economic Cooperation (APEC) Ministers, stated that ethical interactions "with health care professionals, government officials, patients, and other stakeholders are critical to the mission of pharmaceutical sector" to help save lives by developing and making medicines available, notes a posting on the Pharmaceutical and Healthcare Association of the Philippines (PHAP) web site.
In fact, ethical interactions provide a platform for health care professionals to have access to information they need. At the same time, patients ultimately benefit from these interactions as they are able to "access the medicines they need and that medicines are prescribed and used in a manner that provides the maximum health care benefit" to them.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze